Treatment with DLL3-targeted CAR-T cells also resulted in preclinical antitumor activity in SCLC xenograft models [220], and the DLL3-targeting CAR-T cells AMG 119 are in clinical development [221]. The gene discussed is DLL3; the disease is small cell lung carcinoma.